File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma

TitleEntecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma
Authors
KeywordsEntecavir
Hepatocellular carcinoma
Hepatitis B core-related antigen
Chronic hepatitis B
Issue Date2020
PublisherGut and Liver, Editorial Office. The Journal's web site is located at http://www.gutnliver.org/
Citation
Gut and Liver, 2020, Epub 2020-05-29 How to Cite?
AbstractSerum hepatitis B core-related antigen (HBcrAg) was shown to predict the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients undergoing treatment. We investigated the longitudinal profile of HBcrAg in entecavir (ETV)-treated CHB patients with subsequent HCC development. We identified HCC cases diagnosed at ≥1 year after ETV initiation. CHB patients without HCC (matched for age, sex, cirrhosis status, baseline hepatitis B virus (HBV) DNA level, and ETV treatment duration) were identified as controls at an HCC:non-HCC ratio of 1:2. Serum samples were retrieved at baseline (ETV initiation) and at 3 and 5 years of ETV therapy for HBcrAg measurement (log IU/mL). In total, 180 patients (60 HCC patients matched with 120 CHB patients without HCC; median age, 56.5 years; 80.6% male; baseline HBV DNA, 5.9 log IU/mL; median follow-up, 6.8 years) were recruited. The median time from ETV initiation to HCC development was 3.2 years. HBcrAg levels were higher in HCC cases than in controls at all three time points: 5.69 log IU/mL versus 5.02 log IU/mL (p=0.025), 4.23 log IU/mL versus 3.36 log IU/mL (p=0.007), and 3.86 log IU/mL vs 3.36 log IU/mL (p=0.009), respectively. ETV led to similar rates of decline in HBcrAg from baseline to 3 years in both groups (0.34 log IU/mL/year vs 0.39 log IU/mL/year, p=0.774), although the decline from 3 to 5 years was slower in the non-HCC group (0.05 log IU/mL/year) than in the HCC group (0.09 log IU/mL/year, p=0.055). ETV time-dependently reduced HBcrAg in HCC and non-HCC patients. HBcrAg interpretation should consider the antiviral treatment duration.
Persistent Identifierhttp://hdl.handle.net/10722/284088
ISSN
2019 Impact Factor: 3.141
2015 SCImago Journal Rankings: 0.848
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMak, LY-
dc.contributor.authorKo, KL-
dc.contributor.authorTo, WP-
dc.contributor.authorWong, DKH-
dc.contributor.authorSeto, WKW-
dc.contributor.authorFung, JYY-
dc.contributor.authorYuen, RMF-
dc.date.accessioned2020-07-20T05:55:59Z-
dc.date.available2020-07-20T05:55:59Z-
dc.date.issued2020-
dc.identifier.citationGut and Liver, 2020, Epub 2020-05-29-
dc.identifier.issn1976-2283-
dc.identifier.urihttp://hdl.handle.net/10722/284088-
dc.description.abstractSerum hepatitis B core-related antigen (HBcrAg) was shown to predict the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients undergoing treatment. We investigated the longitudinal profile of HBcrAg in entecavir (ETV)-treated CHB patients with subsequent HCC development. We identified HCC cases diagnosed at ≥1 year after ETV initiation. CHB patients without HCC (matched for age, sex, cirrhosis status, baseline hepatitis B virus (HBV) DNA level, and ETV treatment duration) were identified as controls at an HCC:non-HCC ratio of 1:2. Serum samples were retrieved at baseline (ETV initiation) and at 3 and 5 years of ETV therapy for HBcrAg measurement (log IU/mL). In total, 180 patients (60 HCC patients matched with 120 CHB patients without HCC; median age, 56.5 years; 80.6% male; baseline HBV DNA, 5.9 log IU/mL; median follow-up, 6.8 years) were recruited. The median time from ETV initiation to HCC development was 3.2 years. HBcrAg levels were higher in HCC cases than in controls at all three time points: 5.69 log IU/mL versus 5.02 log IU/mL (p=0.025), 4.23 log IU/mL versus 3.36 log IU/mL (p=0.007), and 3.86 log IU/mL vs 3.36 log IU/mL (p=0.009), respectively. ETV led to similar rates of decline in HBcrAg from baseline to 3 years in both groups (0.34 log IU/mL/year vs 0.39 log IU/mL/year, p=0.774), although the decline from 3 to 5 years was slower in the non-HCC group (0.05 log IU/mL/year) than in the HCC group (0.09 log IU/mL/year, p=0.055). ETV time-dependently reduced HBcrAg in HCC and non-HCC patients. HBcrAg interpretation should consider the antiviral treatment duration.-
dc.languageeng-
dc.publisherGut and Liver, Editorial Office. The Journal's web site is located at http://www.gutnliver.org/-
dc.relation.ispartofGut and Liver-
dc.rightsGut and Liver. Copyright © Gut and Liver, Editorial Office.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectEntecavir-
dc.subjectHepatocellular carcinoma-
dc.subjectHepatitis B core-related antigen-
dc.subjectChronic hepatitis B-
dc.titleEntecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma-
dc.typeArticle-
dc.identifier.emailMak, LY: lungyi@hku.hk-
dc.identifier.emailWong, DKH: danywong@hku.hk-
dc.identifier.emailSeto, WKW: wkseto@hku.hk-
dc.identifier.emailFung, JYY: jfung@hkucc.hku.hk-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authorityMak, LY=rp02668-
dc.identifier.authorityWong, DKH=rp00492-
dc.identifier.authoritySeto, WKW=rp01659-
dc.identifier.authorityFung, JYY=rp00518-
dc.identifier.authorityYuen, RMF=rp00479-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.5009/gnl19434-
dc.identifier.pmid32457279-
dc.identifier.scopuseid_2-s2.0-85090913433-
dc.identifier.hkuros310916-
dc.identifier.volumeEpub 2020-05-29-
dc.identifier.isiWOS:000569359000018-
dc.publisher.placeKorea, Republic of-
dc.identifier.issnl1976-2283-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats